Patient prognosis is currently based on a combination of clinical, histopathological and biological features such as age at diagnosis, stage of the disease, MYCN amplification, loss of heterozygosity for chromosome 1p and 11q (LOH1p and LOH11q), tumor ploidy established at diagnosis. Here, MYCN is linked to neoplasm.